![]() All associations between microdosing and STAI-T scores became non-significant when participants with previous macrodose experience (n = 386) were excluded. Current and former microdosers reported lower STAI-T scores compared to microdosing-naïve controls while associations of current and former microdosing with trait anxiety were mediated by trait mindfulness. This cross-sectional study assessed the relationship between microdosing and trait anxiety through an online survey with current microdosers (n = 186), former microdosers (n = 77) and microdosing-naïve controls (n = 234). ![]() Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study Higher ratings of ego dissolution and changes in neuroticism were the strongest predictors of these reductions. The morning after the ceremony, medium reductions in both state and trait anxiety were observed and these reductions persisted for 1-week. Average psilocin consumption across individuals was 27.1 mg. ![]() This naturalistic study (n=52) assessed the effects psilocybin has on measures of state and trait anxiety among retreat participants with subclinical levels of anxiety. This is the first (modern) double-blind placebo-controlled study (n=12) of psilocybin (14mg/70kg) for the treatment of (end-of-life) anxiety (and depression) related to cancer.ĭecreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer Though no significant group difference was found (p=.056), the study showed a large effect size (g=1.03) and a larger sample size might find a significant difference (favouring MDMA). This double-blind, placebo-controlled study (n=18) with MDMA (125mg, 2-3 sessions) in combination with psychotherapy found no significant difference in anxiety in a population with life-threatening illnesses. ![]() MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study Those with more subjective drug effects and mystical-type experiences had better outcomes. The patients, both with and without a life-threatening illness, also improved on measures of depression (HAM-D, BDI). This double-blind cross-over trial (n=42) finds that LSD (200 μg) significantly reduced anxiety (STAI-G) scores up to three months after treatment. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |